INTRODUCTION

Type 2 diabetes mellitus (T2DM) is characterized by the insulin secretion defect and increased insulin resistance [1]. Hyperglycaemia results from a defect in insulin secretion (β-cell dysfunction), hepatic glucose overproduction and peripheral insulin resistance. These features comprise the major characteristics of T2DM [1]. To alleviate these problems, extensive efforts have been made to develop drugs to improve insulin sensitivity and increase insulin secretion from pancreatic β-cells [2]. Recently, the G protein-coupled receptor 119 (GPR119) has emerged as a new therapeutic target for T2DM [3–5]. GPR119 is expressed in pancreatic β-cells, intestinal L-cells, and other tissues, such as the liver [6–8]. Activation of GPR119 leads to enhanced insulin secretion and improved glycaemic control [2,7]. These features of GPR119 make it a potential therapeutic target for T2DM. Several GPR119 agonists have been discovered and entered early clinical trial phases; however, they failed in phase II owing to the loss of efficacy within short duration and tachyphylaxis [5,9]. Unlike other GPR119 agonists, DA-1241 showed long-standing antidiabetic effects in diabetic animal models, as shown in a previous study [10–12]. DA-1241 was reported to exhibit sustained glucose-lowering effects without tachyphylaxis; additionally, it was shown to improve glucose and lipid metabolism [10–12]. These features of DA-1241 made it a promising antidiabetic drug candidate for T2DM.

GPR119 is also expressed in the liver [6,8]; however, its expression level in the liver was relatively lower than that in the pancreas. Although the liver plays an important role in lipid metabolism [13], little has been known about the role of GPR119 in lipid and glucose metabolism in the liver. Hepatic fat accumulation is closely related to hepatic insulin resistance [14,15], the major characteristic of T2DM. A significant portion of the accumulated triglycerides (TG) is derived from hepatic de novo lipogenesis, which increases under conditions of insulin resistance (hyperinsulinaemia) and non-alcoholic fatty liver disease (NAFLD) [14].

It is well known that the liver is the major organ involved in gluconeogenesis [13,15]. During fasting, liver autophagy plays a vital role in blood glucose regulation [16–18]. Amino acids produced from autophagic protein degradation are converted into glucose via gluconeogenesis to maintain the normal plasma glucose levels during fasting [16]. However, hepatic glucose overproduction owing to sustained gluconeogenesis is tightly associated with insulin resistance, a major pathogenic feature of T2DM [19]. The decline in the production of amino acids by autophagy is associated with a decrease in gluconeogenesis [16,18].

Therefore, in this study, we investigated the effects of DA-1241 on insulin secretion from pancreatic β-cells, serum glucagon-like peptide-1 (GLP-1) levels, and liver gluconeogenesis coupled with autophagy in vitro and in vivo. In addition, we evaluated the effects of DA-1241 on fatty liver disease and lipid profile.

METHODS

Cell culture and treatment

HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; SH30243.01, Thermo Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS) (Thermo Scientific, SH30071.03) and 1% penicillin-streptomycin (PS) (Thermo Scientific, SV30010). Prior to experiments, cells were starved for 24 hours in glucose- and serum-free media. Cells were treated with DA-1241 (1,000 nM) for 24 hours, and bafilomycin A1 (20 nM) (B1793, Sigma-Aldrich, St. Louis, St. Louis, MO, USA) was added for 2 hours at the end of time point. DA-1241 was obtained from Dong-A ST. Co. Ltd., Seoul, Korea. Insulinoma cell line (INS-1E) cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Thermo Scientific, SH30027.01) medium supplemented with 10% FBS, 1% PS, and 50 μM β-mercaptoethanol. Prior to the assay, cells were preincubated in Krebs-Ringer bicarbonate buffer (KRBH) (30 mM HEPES, 10 mM NaHCO₃, 120 mM NaCl, 4 mM KH₂PO₄, 1 mM MgSO₄, 1 mM CaCl, and 0.2% bovine serum albumin, adjusted to pH 7.4) containing 1 mM glucose for 1 hour. All cells were incubated at 37°C in a humidified atmosphere containing 5% CO₂.

Western blot analysis

Cells and tissues were lysed in radioimmunoprecipitation assay (RIPA) buffer, containing of 20 mM Tris-HCI (pH 7.5), 150 mM NaCI, 1 mM Na₂ EDTA (ethylenediaminetetraacetic acid), 1 mM EGTA (egtazic acid), 1% NP-40 (ethoxylated nonylphenol), 1% sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na₃Vo₄, 1 μg/mL leupeptin (BRI-9010-010M, Tech & Innovation Co. Ltd., Chuncheon, Korea), and protease inhibitor and phosphatase cocktail (Thermo Scientific, 78440). Protein samples were separated using 10% and 15% polyacrylamide gels and transferred to polyvinylidene fluoride membranes (PVH00010, Millipore, Burlington, MA, USA). The membranes were incubated with the primary antibodies to measure the expression of the following proteins: glucose 6-phosphatase (G6Pase; ab83690, Abcam, Cambridge, UK), phosphoenolpyruvate carboxykinase (PEPCK; Abcam, ab28455), LC3 (Sigma, L7543) and p62 (sc-28359, Santa Cruz, Santa Cruz, CA, USA), and GFP (Abcam, ab13970). Horseradish peroxidase (HRP)-linked anti-mouse immunoglobulin G (IgG; 7076S, Cell signaling, Danvers, MA, USA) and anti-rabbit IgG (Cell signaling, 7074S) were used as secondary antibodies.

Analysis of autophagy flux by fluorescence microscopy

HepG2 cells were transfected with microtubule-associated protein 1 light chain 3-fused to green fluorescent protein and monomeric red fluorescent (mRFP-GFP-LC3) plasmid using Lipofectamine 2000 (1166-027, Invitrogen, Waltham, MA, USA) for 48 hours. Then, cells were fixed in 4% paraformaldehyde (PFA) in phosphate buffer (pH 7.4) for 10 minutes. After fixation, cells were washed with phosphate-buffered saline (three times for 5 minutes) and observed under LSM 700 confocal microscope.

Animal experiments

Four-week-old male C57BL/6J mice were housed under controlled conditions (21°C±2°C, 60%±10% humidity, 12-hour light/12-hour dark cycle). Following acclimatisation, 5-week-old mice were supplemented with high-fat diet (HFD; 60% kcal fat, D12492, Research Diets Inc., New Brunswick, NJ, USA) (n=45) for 8 weeks prior to drug administration. Normal control mice (same age) were fed with normal chow diet (NC) (n=4). After 8 weeks, HFD-induced diabetic mice (blood glucose levels ≥250 mg/dL) were selected and randomised into two groups, HFD (n=10) and HFD+DA-1241 (120 mg/kg) (n=24) groups. Treatment was continued for 12 weeks. Blood glucose levels, body weight, and food intake were monitored weekly. After 12 weeks, mice were anaesthetised with tiletamine-zolazepam (Zoletil, 50 mg/kg; Virbac, Carros, France). Blood samples were collected and stored at −20°C, and liver tissues were isolated, immediately frozen in liquid nitrogen, and stored at −80°C until further analysis. All animal experiments were approved by the Institutional Animal Care and Use Committee at Yonsei University College of Medicine (2016-31-0512) and performed in accordance with relevant guidelines and regulations.

Glucose and insulin tolerance tests and total GLP-1 level measurement

For the oral glucose tolerance test (OGTT), overnight fasted mice were administered 40% glucose (2 g/kg body weight) via oral gavage. Blood glucose levels were measured at 0, 30, 60, 90, and 120 minutes during OGTT. Blood was collected into microcentrifuge tubes, and serum was separated by centrifugation. Serum insulin levels were assessed using a mouse insulin enzyme-linked immunosorbent assay (ELISA) kit (Morinaga Institute of Biological Science Inc., Yokohama, Japan). For total GLP-1 level measurement, blood samples at 0 and 15 minutes time points during the OGTT were collected into tubes containing dipeptidyl peptidase 4 inhibitor (1 mM) (sitagliptin phosphate monohydrate, 1757-1G, BioVision, Milpitas, CA, USA), and serum total GLP-1 level was measured using a GLP-1 total ELISA kit (Cat. #EZGLP1T-36K, Millipore). Insulin tolerance tests (ITTs) were carried out after 4-hour fasting. Insulin (0.75 U/kg) (Sigma-Aldrich, 9177C) was injected insulin intraperitoneally, and blood glucose levels were measured as previously described. In the intraperitoneal glucose tolerance test (GTT), overnight fasted mice were administered glucose intraperitoneally, and blood glucose levels were measured as previously described.

Insulin release assay

Following preincubation as described above, INS-1E cells were washed twice with KRBH and incubated with DA-1241 (1,000 nM) in KRBH containing 2.8 or 16.7 mM glucose for 1 hour. After incubation, the supernatant was centrifuged at 3,000 rpm for 3 minutes, and aliquot of the supernatant was stored at −20°C for analysis. Mouse pancreatic islets were isolated as previously described [20]. Islets were preincubated in low (2.8 mM) glucose for 30 minutes and then, incubated in high (16.7 mM) glucose. Media was collected at 0, 15, 30, 60, and 90 minutes. after high concentration of glucose challenge in both control group and DA-1241 (1,000 nM) treated group. Insulin secretion was measured using a mouse insulin ELISA kit.

Serum lipid profile and fatty liver analysis

Serum samples were sent to RaonBio (Yongin, Korea) for assessment of total TG and cholesterol levels. Hepatic TG contents were measured using a TG quantification kit (Abcam, ab65336).

H&E staining

Tissues were fixed in 4% PFA, embedded in paraffin, and stained with H&E. Lipid accumulation was analysed by an electron microscope.

Statistical analysis

All data were expressed as the mean±standard error of the mean. Statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software, San Diego, CA, USA). Differences between two groups were analysed by Student’s t-test. One-way or two-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc comparison test was used for multiple group comparisons. P values <0.05 were considered statistically significant.

RESULTS

Effects of DA-1241 on glucose tolerance in HFD-fed mice

The scheme of diet and treatment duration is shown in Supplementary Fig. 1. As shown in Fig. 1A-C, body weight gain and food intake were not different between the HFD and DA-1241 groups. Although random blood glucose level was not significantly different between the two groups (Fig. 1D), fasting blood glucose was significantly lower in the DA-1241 group than that in the HFD group (P<0.01) (Fig. 1E).

OGTT showed improved glucose tolerance in the DA-1241 group, compared to that in the HFD group (P<0.01) (Fig. 2A and B). However, intraperitoneal GTT revealed that there was no significant difference in the area under the curve (AUC) between the two groups (P=0.306) (Fig. 2C and D). In addition, insulin tolerance was not different between the HFD and DA-1241 groups (P=0.599) (Fig. 2E and F).

Effects of DA-1241 on serum GLP-1 and insulin levels during OGTT

Serum insulin levels increased in both the HFD and DA-1241 groups compared to the levels in the chow group (Fig. 3A and B). The extent of increase in serum insulin level 30 minutes after oral glucose challenge was significantly higher in the DA-1241 group than that in the HFD group (P<0.05) (Fig. 3B). To represent insulin resistance, we have assessed homeostatic model assessment for insulin resistance (HOMA-IR) from HOMA-IR=glucose (mg/dL)×insulin (μIU/mL)/405 [21]. DA-1241 increased the insulinogenic index, compared to that in the HFD group (Supplementary Fig. 2A). Matsuda index, a whole body insulin sensitivity index [22], revealed that insulin resistance was not different between the DA-1241 and HF groups (Supplementary Fig. 2B). To determine whether the improvement in insulin secretion was attributed to direct insulin secretory response from the pancreatic β-cells, we investigated the effects of DA-1241 on insulin secretion in INS-1E cells. In glucose-stimulated insulin secretion (GSIS) assays, DA-1241 did not increase insulin secretion under high-glucose (16.7 mM) or in low-glucose conditions in INS-1E cells (Fig. 3C). In addition, we evaluated GSIS in isolated mouse pancreatic islets. DA-1241 did not show augmented insulin secretion in mouse islets in response to glucose challenge (Fig. 3D). The levels of serum total GLP-1 were measured during the OGTT. DA-1241 group exhibited higher total GLP-1 level than that in the HFD group (P<0.01) (Fig. 3E).

Effects of DA-1241 on fatty liver and serum lipid profile

Liver tissues were collected from overnight-fasted mice after the 12-week study period. Liver sections were analysed by hematoxylin and eosin (H&E) staining. As shown in Fig. 4A, DA-1241 considerably diminished lipid accumulation, whereas the HFD group showed marked lipid accumulation. Hepatic TG contents decreased in the DA-1241 group to levels similar to those in the NC group (P<0.05) (Fig. 4B). DA-1241 group showed significant reduction of serum cholesterol levels, compared to those in the HFD group (P<0.01) (Fig. 4C). Serum TG contents were not different among the three groups (P=0.463) (Fig. 4D). We showed that DA-1241 improved fatty liver without changes in body weight (Fig. 1A and B).

Effects of DA-1241 on gluconeogenic enzyme expression and autophagy flow

HepG2 cells were treated with DA-1241 for 24 hours under starved conditions. As shown in Fig. 5A, the expression of G6Pase and PEPCK, the rate-limiting enzymes in gluconeogenesis [13] decreased in DA-1241-treated cells. We measured protein level of PEPCK and G6Pase in the liver tissue of chow treated mice, HFD treated mice, and HFD+DA-1241 treated mice. G6PC and PEPCK protein expression increased with HFD, DA-1241 treatment attenuated the protein expression of both gluconeogenic enzymes (Fig. 5B).

To investigate the effects of DA-1241 treatment on autophagic flux, we measured the protein levels of LC3-II and p62 in the absence and presence of bafilomycin A1, an autophagy blocker [23], in HepG2 cells by Western blot analysis. LC3-I to II conversion increased after DA-1241 treatment, which was augmented by bafilomycin A1 pre-treatment (Fig. 5C). However, p62 expression increased after DA-1241 treatment (Fig. 5C).

To monitor autophagic flux in vitro, HepG2 cells were transfected with mRFP-GFP-LC3 expression vector. An increase in the number of red puncta reflects autophagic flux [24]. Autophagy-induced cells showed an increase in the number of yellow puncta, compared to cells under normal conditions (white bar) (Fig. 6A and B). In the absence of bafilomycin A1, the number of red puncta was markedly lower in DA-1241-treated cells than that in the control cells, indicating that DA-1241 reduced autophagic flux in HepG2 cells (Fig. 6A and C). Bafilomycin A1 treatment resulted in an increase in the number of yellow puncta (Fig. 6B) with a decrease in the number of red puncta (Fig. 6C), regardless of DA-1241 treatment.

DISCUSSION

GPR119 is expressed in the pancreatic β-cells, intestinal L-cells, and other tissues, such as the liver; however, its expression in the liver was relatively lower than that in the pancreas [6–8,25]. Some studies reported that GPR119 directly augmented insulin secretion from β-cells [7,26], and other studies showed that GRP119 activation indirectly induced glucose-dependent insulin secretion through the release of incretin hormone [7,27,28].

The glucose-lowering effects of GPR119 agonists were verified in several studies [7,8,29]. In addition, GPR119-deficient mice showed loss of the antihyperglycaemic effects of GPR119 agonist in GTT [7]. To evaluate the sustained glucose-lowering effects of DA-1241, DA-1241 was administered for 12 weeks in HFD-induced diabetic mice. Results of GTT revealed that DA-1241 improved glycaemic control with an improvement in insulin secretion. These glucose-lowering effects lasted for 12 weeks.

To test whether DA-1241 augmented glucose-stimulated insulin release directly from pancreatic β-cells, we performed GSIS assays in INS-1E, rat β-cell lines [30]. Although previous studies showed that GPR119 directly increased insulin secretion from pancreatic β-cell lines [6,26,31], in this study, DA-1241 did not exhibit any direct effects on insulin secretion from INS-1E cells. Our findings are in line with the results of some prior studies, showing the synthetic GPR119 agonists did not augmented glucose-dependent insulin secretion from INS-1 cells [32]. However, various studies showed that GPR119 agonists increased cyclic adenosine monophosphate (cAMP) levels and enhanced insulin secretion from HIT-T15 cells, a hamster β-cell line, or mouse insulinoma (MIN6) cells.

Therefore, it is possible that the effect of DA-1241 on insulin secretion is different according to beta lines. Additionally, several studies showed that GPR119 agonists increased insulin secretion from pancreatic islets [7,33], whereas one study reported conflicting results [34]. Thus, it cannot be ruled out that primary mouse β-cells can be responsive to DA-1241.

GPR119 agonists have been shown to enhance insulin secretion in a glucose-dependent manner through GLP-1 release [8,29,34]. Therefore, we hypothesised that DA-1241 might stimulate GLP-1 secretion and regulate glucose homeostasis. Consistent with previous findings, DA-1241 substantially enhanced serum GLP-1 levels during OGTT. Since GLP-1 decreases blood glucose levels in a nutrient-dependent manner [35], this effect of GPR119 agonists could minimise the risk of hypoglycaemia. A previous study demonstrated that intraperitoneal GTT and ITT were not different between Gpr119^−/− and Gpr119^+/+ mice [34]. Consistently, we observed no significant difference in intraperitoneal GTT and ITT between HFD-fed mice and DA-1241-treated mice. Therefore, we suggested that antihyperglycaemic effects of DA-1241 might be attributed to improved GLP-1 secretion upon oral glucose challenge.

GLP-1 not only indirectly enhances GSIS from β-cells but also protects β-cell mass via inhibition of apoptosis [35]. Moreover, GLP-1 is involved in the regulation of appetite [35,36]. Activated GLP-1 inhibits gastric emptying and food intake [35], which might partly contribute to its glucose-lowering effects. Because GPR119 agonists exhibited GLP-1 mimetic effects, they can be promising antidiabetic drug candidates for T2DM. It was reported that oleoylethanolamide, an endogenous ligand of GPR119, reduced food intake via activation of GPR119 receptor [37]. Although our study showed that DA-1241 substantially increased GLP-1 levels, GLP-1 secretion did not significantly affect food consumption. This findings might be explained by the differences in the signaling pathways activated by endogenous and synthetic GPR119 agonists [38]. However, the underlying mechanisms remain unclear.

GLP-1 increases cAMP levels and subsequently stimulates cAMP-activated protein kinase (AMPK) and inhibits sterol regulatory element-binding protein 1C (SREBP-1C), leading to inhibition of hepatic lipogenesis [39,40]. A recent study verified the expression of GPR119 mRNA and protein in human and mouse hepatocytes [41], and showed that MBX2982, a GPR119 agonist, attenuated hepatic steatosis via stimulation of AMPK phosphorylation, which suppressed the expression of SREBP-1C and consequently inhibited lipogenesis in the liver [41–43]. Because the liver plays a vital role in lipid metabolism [13], we studied the long-term effects of DA-1241 treatment on lipid profile in HFD-induced diabetic mice. In line with the results of lipid accumulation assays, chronic administration of DA-1241 reduced hepatic TG contents, which might be related to SREBP-1C-mediated lipogenic enzyme inhibition [42]. DA-1241 also considerably decreased total cholesterol levels, which is beneficial for NAFLD [44]. However, DA-1241 had a little effect on total TG levels. Similarly, APD668, a GPR119 agonist, reduced hepatic TG and total cholesterol levels, but not plasma TG levels, suggesting that ADP668 decreased postprandial TG levels, without affecting TG synthesis [39].

It has been reported that liver autophagy contributes to restoring blood glucose level via gluconeogenesis [16–18]. Liver-specific Atg7-deficient mice showed substantially reduced blood glucose levels under starvation conditions [16]. In HepG2 cells, starvation-induced autophagy was blocked by chloroquine (CQ), an autophagy blocker, and the expression of G6Pase and PEPCK was suppressed by CQ treatment [18]. Based on the results of previous studies, we examined whether DA-1241-induced autophagy blockade could affect gluconeogenesis in the liver. In our study, gluconeogenic enzyme expression was downregulated owing to the blockade of autophagic flux in cells and mice treated with DA-1241. Collectively, we suggested that autophagy blockade by DA-1241 partly contributed to the reduction of gluconeogenic enzyme expression in the liver. Furthermore, liver-specific Atg7-knockout mice (Atg7^Δhep mice) exhibited improved glucose homeostasis and reduced fatty acid and triacylglycerol synthesis-related gene expression, with diminished hepatic lipid accumulation [45]. Although further studies are needed to clarify the role of autophagy in lipid metabolism [46–48], our findings presented new perspective of the effects of autophagy blockade by GPR119 agonists on glucose homeostasis and lipid metabolism, implying that DA-1241 might be a novel antidiabetic drug candidate.

Herein, we evaluated the antidiabetic effects of DA-1241 in vitro and in vivo. DA-1241 improved glucose tolerance without reduction of body weight. These glucose-lowering effects lasted for 12 weeks. Although DA-1241 augmented insulin secretion, it did not exhibit direct effects on insulin release from pancreatic β-cell lines. However, this could be explained that primary β-cells might be more responsive to DA-1241 than pancreatic β-cell lines. DA-1241 considerably enhanced GLP-1 secretion; however, it did not alter food intake.

Taken together, our study suggested that DA-1241, a novel GPR119 agonist, resulted in improved glycaemic control by increasing glucose-dependent insulin release via improvement of GLP-1 secretion, rather than directly affecting the pancreatic β-cells. Additionally, it reduced hepatic gluconeogenesis, which might be associated with autophagic blockade.

SUPPLEMENTARY MATERIALS

NOTES

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS

Conception or design: Y.K., E.S.K.

Acquisition, analysis, or interpretation of data: Y.K., S.W.L., H.W., R.H.K., H.K.P., H.L., E.S.K.

Drafting the work or revising: Y.K., S.W.L., E.S.K.

Final approval of the manuscript: E.S.K.

FUNDING

This work was supported by a research grant of the Bio & Medical Technology Development Program of the NRF, Korea, MSIP (2019R1A2C2007514).

Acknowledgements

ACKNOWLEDGMENTS

None

Fig. 1

Basal metabolic rate characterization. During the study period, body weight, random blood glucose levels, and food intake were monitored weekly. (A) Body weight. (B) Body weight after 12 weeks of study period. There was no significant difference in body weight among groups. (C) Food intake. (D) Average random blood glucose level. (E) Fasting blood glucose level after 12 weeks of study period. Random blood glucose level was not different among groups; however, fasting blood glucose level was considerably reduced in the DA-1241 group. Data are presented as the mean±standard error of the mean. ^aP<0.01, compared with high-fat (HF) group (chow, n=4; HF, n=10; DA-1241, n=24), ^bP<0.001.

Fig. 2

Effects of DA-1241 on glucose tolerance and insulin tolerance tests (ITTs) in high-fat (HF) diet-fed mice. (A, B) Blood glucose excursion and area under the curve (AUC) during oral glucose tolerance test (OGTT) at week 8. DA-1241 improved glucose tolerance with a substantial decrease in AUC during OGTT. (C, D) Blood glucose excursion and AUC during intraperitoneal glucose tolerance test (IPGTT) at week 11. (E, F) Glucose levels and AUC during ITT at week 10. No significant differences in AUC of intraperitoneal GTT and ITT were observed between the HF diet and DA-1241 groups. Data are presented as the mean±standard error of the mean. ^aP<0.05, ^bP<0.01, compared with HF group (chow, n=4; HF, n=10; DA-1241, n=24), ^cP<0.001.

Fig. 3

Measurement of insulin secretion and serum total glucagon-like peptide-1 (GLP-1) levels. (A) Serum insulin levels were determined at 0 and 30 minutes during oral glucose tolerance test (OGTT) at week 8. (B) Change in serum insulin levels during OGTT. The DA-1241 group exhibited enhanced insulin levels. (C) Insulin levels in insulinoma cell line (INS-1E) cells after incubation with DA-1241 for 1 hour under low- and high-glucose conditions. Measurements were carried out in triplicate. DA-1241 did not enhance insulin secretion from INS-1E cells in response to high glucose concentrations. (D) Islets were preincubated in low- (2.8 mM) glucose for 30 minutes and then, incubated in high (16.7 mM) glucose. Insulin levels in mouse islets after incubation with DA-1241 (1,000 nM) under high glucose conditions. Insulin group of five islets. (E) Serum total GLP-1 levels increased after DA-1241 treatment. Serum total GLP-1 levels were determined at 0 and 15 minutes during OGTT at week 8. Data are presented as the mean±standard error of the mean. ^aP<0.05, ^bP<0.01, compared with HF group (chow, n=4; high-fat [HF], n=10; DA-1241, n=24), ^cP<0.001.

Fig. 4

Effects of DA-1241 on fatty liver and serum lipid profile. Blood samples and liver tissues were collected from overnight-fasted mice after 12 weeks of study period. (A) Liver sections were analysed by H&E staining. Images were obtained using an electron microscope at 20× magnification. Hepatic lipid accumulation was markedly diminished in the DA-1241 group. (B) Liver triglyceride (TG), (C) serum cholesterol, and (D) serum TG contents were measured after 12 weeks of study period. The DA-1241 group showed a considerable decrease in liver TG and serum total cholesterol, but not in serum TG levels. Data are presented as the mean±standard error of the mean. ^aP<0.05, ^bP<0.01, compared with HF group (chow, n=4; high-fat [HF], n=10; DA-1241, n=24).

Fig. 5

Effects of DA-1241 on gluconeogenic and autophagic enzyme expression. (A) Protein expression levels of glucose 6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) in HepG2 cells treated with DA-1241 (1,000 nM) for 24 hours under starvation conditions. DA-1241 reduced G6Pase and PEPCK expression in HepG2 cells. (B) Protein expression levels of G6Pase and PEPCK in liver tissue of chow, high-fat diet (HFD), and HFD-DA 1241 group. DA-1241 treatment reduced G6pase and PEPCK compared to HFD group. (C) Protein levels of LC3 and p62 in HepG2 cells treated with DA-1241 (1,000 nM) for 24 hours in the presence or absence of bafilomycin A1 (20 nM) for 2 hours. DA-1241 reduced LC3 levels and enhanced p62 levels in HepG2 cells.

Fig. 6

Monitoring of autophagic flux in HepG2 cells. HepG2 cells were transfected with microtubule-associated protein 1 light chain 3-fused to green fluorescent protein and monomeric red fluorescent (mRFP-GFP-LC3) expression vector. Then, HepG2 cells were treated with DA-1241 (1,000 nM) for 24 hours, and bafilomycin A1 (20 nM) was added for 2 hours. Cells under normal conditions were used as a control. (A) Images were obtained using a confocal microscope at 40× magnification. (B) Quantification of the number of LC3 and (C) mRFP/GFP-LC3 ratio. DA-1241 increased LC3 puncta (yellow) and decreased mRFP puncta (red) in HepG2 cells. Data are presented as the mean±standard error of the mean. ^aP<0.01, ^bP<0.001, compared with control (CTL) (white bars) (n=6).

REFERENCES

• 1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005;365:1333-46.ArticlePubMed
• 2. Shah U, Kowalski TJ. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders. Vitam Horm 2010;84:415-48.ArticlePubMed
• 3. Overton HA, Fyfe MC, Reynet C. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 2008;153(Suppl 1):S76-81.ArticlePubMedPDF
• 4. Jones RM, Leonard JN, Buzard DJ, Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat 2009;19:1339-59.ArticlePubMed
• 5. Yang JW, Kim HS, Choi YW, Kim YM, Kang KW. Therapeutic application of GPR119 ligands in metabolic disorders. Diabetes Obes Metab 2018;20:257-69.PubMed
• 6. Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005;326:744-51.ArticlePubMed
• 7. Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148:2601-9.PubMed
• 8. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release. Endocrinology 2008;149:2038-47.ArticlePubMedPDF
• 9. Kang SU. GPR119 agonists: a promising approach for T2DM treatment?: a SWOT analysis of GPR119. Drug Discov Today 2013;18:1309-15.ArticlePubMed
• 10. Kim M, Kim T, Choeng Y, Chae Y, Jung I, Lee K, et al. Long-term treatment of DA-1241, a novel GPR119 agonist, improved glucose control via preserved beta cell mass in a progressive diabetic mice model. Diabetes 2015 64(Suppl 1):280.LB.
• 11. Kim MK, Kim TH, Lee S, Jung IH, Chea YN, Yang JS. Effects of DA-1241, a novel GPR-119 agonist, on lipid control in disease models mediated by regulating an AMPK/SREBP1c signaling path. Diabetes 2017 66(Suppl 1):161.LB.
• 12. Kim YJ, Kim RH, Park HK, Cho YI, Lee MY, Lee JY, et al. 139-PE: DA-1241, a novel GPR119 agonist, improves glycemia via inhibition of hepatic gluconeogenesis and enhancing glucose stimulated insulin action via stimulating GLP-1 secretion in intestine. In: Proceedings of International Congress of Diabetes and Metabolism 2018; 2018 Oct 11–13; Seoul, KR.
• 13. Rui L. Energy metabolism in the liver. Compr Physiol 2014;4:177-97.ArticlePubMedPMCPDF
• 14. Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol 2014;20:9072-89.PubMedPMC
• 15. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012;56:952-64.ArticlePubMed
• 16. Ezaki J, Matsumoto N, Takeda-Ezaki M, Komatsu M, Takahashi K, Hiraoka Y, et al. Liver autophagy contributes to the maintenance of blood glucose and amino acid levels. Autophagy 2011;7:727-36.ArticlePubMedPMC
• 17. Wang HJ, Park JY, Kwon O, Choe EY, Kim CH, Hur KY, et al. Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction. Autophagy 2015;11:2089-101.ArticlePubMedPMC
• 18. Jeon JY, Lee H, Park J, Lee M, Park SW, Kim JS, et al. The regulation of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase by autophagy in low-glycolytic hepatocellular carcinoma cells. Biochem Biophys Res Commun 2015;463:440-6.ArticlePubMed
• 19. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus: a 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-7.ArticlePubMedPMC
• 20. Li DS, Yuan YH, Tu HJ, Liang QL, Dai LJ. A protocol for islet isolation from mouse pancreas. Nat Protoc 2009;4:1649-52.ArticlePubMedPDF
• 21. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab 2015;19:160-4.ArticlePubMedPMC
• 22. Patarrao RS, Lautt WW, Macedo MP. Assessment of methods and indexes of insulin sensitivity. Rev Port Endocrinol Diabetes Metab 2014;9:65-73.Article
• 23. Mizushima N, Yoshimori T. How to interpret LC3 immunoblotting. Autophagy 2007;3:542-5.ArticlePubMed
• 24. Yoshii SR, Mizushima N. Monitoring and measuring autophagy. Int J Mol Sci 2017;18:1865.ArticlePubMedPMC
• 25. Odori S, Hosoda K, Tomita T, Fujikura J, Kusakabe T, Kawaguchi Y, et al. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function. Metabolism 2013;62:70-8.ArticlePubMed
• 26. Moran BM, Abdel-Wahab YH, Flatt PR, McKillop AM. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice. Biol Chem 2014;395:453-64.ArticlePubMed
• 27. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987;84:3434-8.ArticlePubMedPMC
• 28. Lauffer LM, Iakoubov R, Brubaker PL. GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 2009;58:1058-66.ArticlePubMedPMCPDF
• 29. Kim SR, Kim DH, Park SH, Kim YS, Kim CH, Ha TY, et al. In vivo efficacy of HD0471953: a novel GPR119 agonist for the treatment of type 2 diabetes mellitus. J Diabetes Res 2013;2013:269569.ArticlePubMedPMCPDF
• 30. Skelin M, Rupnik M, Cencic A. Pancreatic beta cell lines and their applications in diabetes mellitus research. ALTEX 2010;27:105-13.ArticlePubMed
• 31. Han T, Lee BM, Park YH, Lee DH, Choi HH, Lee T, et al. YH18968, a novel 1,2,4-triazolone G-protein coupled receptor 119 agonist for the treatment of type 2 diabetes mellitus. Biomol Ther (Seoul) 2018;26:201-9.ArticlePubMedPMC
• 32. Stone VM, Dhayal S, Smith DM, Lenaghan C, Brocklehurst KJ, Morgan NG. The cytoprotective effects of oleoylethanolamide in insulin-secreting cells do not require activation of GPR119. Br J Pharmacol 2012;165:2758-70.ArticlePubMedPMC
• 33. Flock G, Holland D, Seino Y, Drucker DJ. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 2011;152:374-83.ArticlePubMedPDF
• 34. Panaro BL, Flock GB, Campbell JE, Beaudry JL, Cao X, Drucker DJ. β-Cell inactivation of Gpr119 unmasks incretin dependence of GPR119-mediated glucoregulation. Diabetes 2017;66:1626-35.ArticlePubMedPMCPDF
• 35. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-65.ArticlePubMed
• 36. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.ArticlePubMedPDF
• 37. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006;3:167-75.ArticlePubMed
• 38. Ning Y, O’Neill K, Lan H, Pang L, Shan LX, Hawes BE, et al. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol 2008;155:1056-65.ArticlePubMedPMCPDF
• 39. Bahirat UA, Shenoy RR, Goel RN, Nemmani KV. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice. Eur J Pharmacol 2017;801:35-45.ArticlePubMed
• 40. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol 2011;54:1214-23.ArticlePubMed
• 41. Yang JW, Kim HS, Im JH, Kim JW, Jun DW, Lim SC, et al. GPR119: a promising target for nonalcoholic fatty liver disease. FASEB J 2016;30:324-35.ArticlePubMedPDF
• 42. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004;86:839-48.ArticlePubMed
• 43. Yamamoto T, Shimano H, Inoue N, Nakagawa Y, Matsuzaka T, Takahashi A, et al. Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem 2007;282:11687-95.ArticlePubMed
• 44. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 2015;1852:1765-78.ArticlePubMed
• 45. Kim KH, Jeong YT, Oh H, Kim SH, Cho JM, Kim YN, et al. Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokine. Nat Med 2013;19:83-92.ArticlePubMedPDF
• 46. Shibata M, Yoshimura K, Furuya N, Koike M, Ueno T, Komatsu M, et al. The MAP1-LC3 conjugation system is involved in lipid droplet formation. Biochem Biophys Res Commun 2009;382:419-23.ArticlePubMed
• 47. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, et al. Autophagy regulates lipid metabolism. Nature 2009;458:1131-5.ArticlePubMedPMCPDF
• 48. Kwanten WJ, Martinet W, Michielsen PP, Francque SM. Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue. World J Gastroenterol 2014;20:7325-38.ArticlePubMedPMC

Figure & Data

References

Citations

Citations to this article as recorded by  

• Discovery of 1,4-Disubstituted Cyclohexene Analogues as Selective GPR119 Agonists for the Treatment of Type 2 Diabetes
  Hyunhwa La, Jinwoong Kim, Dae-Hoon Kim, Seong-Heon Kim, Pargat Singh, Gibeom Nam, Kyeongwon Moon, Ikyon Kim, In Su Kim
  Journal of Medicinal Chemistry.2025; 68(4): 4619.     CrossRef
• Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
  Aditi Singh, Sucharita Shadangi, Pulkit Kr. Gupta, Soumendra Rana
  Comprehensive Physiology.2025;[Epub]     CrossRef
• Unraveling the Mystery of Insulin Resistance: From Principle Mechanistic Insights and Consequences to Therapeutic Interventions
  Mohammad Muzaffar Mir, Mohammed Jeelani, Muffarah Hamid Alharthi, Syeda Fatima Rizvi, Shahzada Khalid Sohail, Javed Iqbal Wani, Zia Ul Sabah, Waad Fuad BinAfif, Partha Nandi, Abdullah M. Alshahrani, Jaber Alfaifi, Adnan Jehangir, Rashid Mir
  International Journal of Molecular Sciences.2025; 26(6): 2770.     CrossRef
• Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment
  Barbara Gieroba, Adrianna Kryska, Anna Sroka-Bartnicka
  Biochemistry and Biophysics Reports.2025; 42: 102037.     CrossRef
• DA-1241, a GPR119 Agonist, Ameliorates Fatty Liver Through the Upregulation of TFEB-Mediated Autophagy
  Jin Yoo, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, Myung-Shik Lee, You-Cheol Hwang
  Diabetes.2025; 74(7): 1107.     CrossRef
• G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?
  Mohan Patil, Ilaria Casari, Leon N. Warne, Marco Falasca
  Biomedicine & Pharmacotherapy.2024; 172: 116245.     CrossRef
• GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates
  Deanne H Hryciw, Rhiannon K Patten, Raymond J Rodgers, Joseph Proietto, Dana S Hutchinson, Andrew J McAinch
  Expert Opinion on Investigational Drugs.2024; 33(3): 183.     CrossRef
• Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment
  Katarzyna Napiórkowska-Baran, Paweł Treichel, Marta Czarnowska, Magdalena Drozd, Kinga Koperska, Agata Węglarz, Oskar Schmidt, Samira Darwish, Bartłomiej Szymczak, Zbigniew Bartuzi
  International Journal of Molecular Sciences.2024; 25(7): 3769.     CrossRef
• Advances in small-molecule insulin secretagogues for diabetes treatment
  Jingqian Su, Jingran Xu, Shan Hu, Hui Ye, Lian Xie, Songying Ouyang
  Biomedicine & Pharmacotherapy.2024; 178: 117179.     CrossRef
• Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?
  Khaled Al Smadi, Ammar Qureshi, Besher Ashouri, Zeid Kayali
  Expert Opinion on Investigational Drugs.2024; 33(9): 877.     CrossRef
• Chronic metabolic effects of novel gut-oriented small-molecule GPR119 agonists in diet-induced obese mice
  Mohan Patil, Dinesh Thapa, Leon N. Warne, Ricky R. Lareu, Elena Dallerba, Jerome Lian, Massimiliano Massi, Rodrigo Carlessi, Marco Falasca
  Biomedicine & Pharmacotherapy.2024; 181: 117675.     CrossRef
• Ganoderma lucidum Spore Powder Alleviates Metabolic-Associated Fatty Liver Disease by Improving Lipid Accumulation and Oxidative Stress via Autophagy
  Yuxuan Zhang, Jiali Zhou, Lan Yang, Hang Xiao, Dongbo Liu, Xincong Kang
  Antioxidants.2024; 13(12): 1501.     CrossRef
• Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists
  Heecheol Kim, Minjung Kim, Kyujin Oh, Sohee Lee, Sunyoung Lim, Sangdon Lee, Young Hoon Kim, Kwee Hyun Suh, Kyung Hoon Min
  European Journal of Medicinal Chemistry.2023; 258: 115584.     CrossRef
• Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
  Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
  Metabolism.2023; 145: 155612.     CrossRef
• Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis
  Karolien Buyl, Martine Vrints, Ruani Fernando, Terry Desmae, Thomas Van Eeckhoutte, Mia Jans, Jan Van Der Schueren, Joost Boeckmans, Robim M. Rodrigues, Veerle De Boe, Vera Rogiers, Joery De Kock, Filip Beirinckx, Tamara Vanhaecke
  European Journal of Pharmacology.2023; 957: 175989.     CrossRef
• GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling
  Seung-Ho Lee, Hansu Park, Eun-Kyoung Yang, Bo Ram Lee, Il-Hoon Jung, Tae-Hyoung Kim, Moon Jung Goo, Yuna Chae, Mi-Kyung Kim
  Biomedicine & Pharmacotherapy.2023; 166: 115345.     CrossRef
• Characteristics of the Latest Therapeutic Agent for Diabetes
  Nuri Yun
  The Journal of Korean Diabetes.2023; 24(3): 148.     CrossRef
• DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice
  Youjin Kim, Si Woo Lee, Hyejin Wang, Ryeong-Hyeon Kim, Hyun Ki Park, Hangkyu Lee, Eun Seok Kang
  Diabetes & Metabolism Journal.2022; 46(2): 337.     CrossRef
• Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
  Chun-Liang Chen, Yu-Cheng Lin
  International Journal of Molecular Sciences.2022; 23(17): 10055.     CrossRef

About this article

Kim Y, Lee SW, Wang H, Kim RH, Park HK, Lee H, Kang ES. DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice. Diabetes Metab J. 2022;46(2):337-348.

Received: Mar 24, 2021; Accepted: Aug 12, 2021

DOI: https://doi.org/10.4093/dmj.2021.0056.

Download citation ↓